Key facts
- This page summarizes Steve Pakola's Form 4 filing for REGENXBIO Inc. (RGNX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Aug 2026, 16:30.
Steve Pakola - 01 Aug 2026 Form 4 Insider Report for REGENXBIO Inc. (RGNX)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- RGNX
- Reported as of
- 01 Aug 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Aug 2026, 16:30:31 UTC
- Prior SEC filing
- 06 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick J. Christmas as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Steve Pakola filed Form 4 for REGENXBIO Inc. (RGNX) on 04 Aug 2026.
Change
- Previous filing in this sequence was filed on 06 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001700659
Primary reporting owner
PAKOLA STEVE
- Relationship
- Chief Medical Officer
- Address
- C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE
- Signature
- /s/ Patrick J. Christmas as attorney-in-fact
- Signature date
- 04 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RGNX
transaction
Common Stock
Tax liability
- Transaction value
- Shares
- -7,468
- Change %
- -3.5%
- Price
- $9.69*
- Shares after
- 205,541
- Date
- 01 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on August 1, 2026.